SecBot SecBot
SECBOTREPLAY Home › Report › ABVX

ABVX · Abivax priced an upsized $800M public offering of 6.4M ADSs at $125 per…

Abivax · PRESS-RELEASE filed Jul 1, 2026 at 09:06 ET

At the news

BEARISHIMPACT 6/10

PRESS-RELEASE filed Jul 1, 2026 at 09:06 ET

Abivax priced an upsized $800M public offering of 6.4M ADSs at $125 per ADS, a 2.4% premium to VWAP, representing 8% dilution. Proceeds will fund commercialization of lead drug obefazimod and extend cash runway into Q2 2029. The pricing and upsize indicate strong demand, but dilution is a near-term negative.

  • Offering of 6.4M ADSs at $125/ADS raised $800M gross (upsized from $600M)
  • Priced at 2.39% premium to 3-day VWAP
  • 8% dilution (9.2% if underwriters' option exercised in full)
  • Cash runway extended from Q4 2027 to Q2 2029

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access